Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: childrenacutenewsmallknown
  Phrases that lowered it: healthytabletbioavailabilitythe pharmacokineticscompare
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Primary purpose: not given (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 6.1% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 110 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 11.7% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Maximum age: 55 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 96.4% (raises risk) · Drug's FDA history
• Sponsor's past trials: 545 (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet NCT01853800 · started 2013 · scored riskier than 0% of active trials completed
• Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions NCT07807488 · started 2022 · scored riskier than 0% of active trials completed
• Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban NCT01436526 · started 2009 · scored riskier than 0% of active trials completed
• Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants NCT01464450 · started 2011 · scored riskier than 1% of active trials completed
• Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects NCT04511611 · started 2019 · scored riskier than 0% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.